11月20日，翰森制药(03692)盘中上涨5.01%，截至10:39，报18.02元/股，成交6809.64万元。
翰森制药集团有限公司是一家中国领先的创新驱动型制药企业，主要关注抗肿瘤、抗感染、中枢神经系统类疾病、代谢疾病及自身免疫性疾病等领域。公司已经成功研发并上市了7款创新药，其中6款首个中国原研1类新药，经过几年积累已经具有高效的创新药物发现能力，并且研发覆盖单抗、ADC药物、siRNA、双抗及融合蛋白产品等领域，现有超过30个处于临床阶段的创新药项目，形成了丰富且具有竞争力的研发管线。2023年总营收突破百亿规模，其中创新产品营收占比67.9%。
截至2024年中报，翰森制药营业总收入65.06亿元、净利润27.26亿元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.